Lenvatinib 4mg & Availability | Multikinase Inhibitor

What Is Lenvatinib and How Does It Work?

Lenvatinib is an orally administered multikinase inhibitor indicated across several advanced oncology settings. Its therapeutic activity is rooted in the selective inhibition of key receptor tyrosine kinases that drive pathologic angiogenesis — the process by which tumors generate new blood vessel networks to sustain their growth and spread.

Specifically, lenvatinib inhibits the kinase activities of vascular endothelial growth factor receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4), along with other kinases implicated in pathologic angiogenesis and tumor proliferation. By simultaneously targeting multiple kinase pathways, lenvatinib disrupts the signaling cascades that tumors depend on for vascular support and growth — a mechanism that distinguishes multikinase inhibitors from agents targeting a single receptor.

Lenvatinib received FDA approval on February 13, 2015, establishing it as a clinically validated option in the management of certain refractory and advanced malignancies. Its oral capsule formulation supports outpatient administration, which is a practical consideration for oncology procurement and patient management programs in markets such as Pakistan.

Approved Indications: What Conditions Is Lenvatinib Used For?

Lenvatinib is approved across four distinct oncology indications, reflecting its broad kinase inhibition profile and clinical utility in multiple tumor types.

As a kinase inhibitor with activity across these four tumor types, lenvatinib represents a therapeutically versatile agent for oncology formularies and procurement programs serving hospitals and specialty cancer centers.

Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Differentiated thyroid cancer encompasses the most common histologic subtypes of thyroid malignancy, including papillary and follicular carcinomas. In early-stage disease, radioactive iodine (RAI) therapy is a well-established treatment modality that exploits the iodine-uptake capacity of differentiated thyroid cells. However, a clinically significant subset of patients develops progressive disease despite RAI treatment — a condition defined as radioactive iodine-refractory DTC.

In this refractory setting, tumor cells lose their ability to concentrate iodine, rendering RAI ineffective. Disease may become locally recurrent or metastatic, and patients require systemic therapeutic options capable of targeting the molecular drivers of continued tumor progression.

This is where lenvatinib’s multikinase inhibition mechanism becomes directly relevant. By blocking VEGFR1, VEGFR2, VEGFR3, and additional kinases involved in pathologic angiogenesis and tumor growth, lenvatinib targets the vascular and proliferative signaling that sustains tumor expansion in the RAI-refractory state. The inhibition of these angiogenic pathways can impair the tumor’s ability to develop the blood supply necessary for continued growth — a mechanism that underpins its use in this indication.

For oncologists and procurement specialists evaluating systemic options for locally recurrent or metastatic, progressive, radioactive iodine-refractory DTC, lenvatinib represents an FDA-approved, mechanism-driven therapeutic choice with a clearly defined molecular rationale. Bangladeshi-manufactured brands Lanib, Lenvaxen, and Lenvanix supply this active molecule for clinical use.

Available Strengths and Dosage Forms

Lenvatinib is available as oral capsules in two strengths: 4 mg and 10 mg. Both forms are supplied as hard capsules intended for oral administration.

The 4 mg capsule is yellowish-red in appearance and carries the imprint code E;LENV;4;mg, which supports identification and dispensing accuracy at the pharmacy level. The active substance, lenvatinib mesylate, is described as a white to pale reddish yellow powder within the capsule formulation.

Lenvatinib capsules should be swallowed as directed. All specific dosing decisions — including regimen selection, dose adjustments, and management of dose modifications — are determined exclusively by the treating oncologist in accordance with the official prescribing information. Healthcare providers and procurement teams should refer to the full prescribing information for complete administration guidance.

Both the 4 mg and 10 mg capsule strengths are available through the Bangladeshi-manufactured brands supplied by our organization for export to Pakistan and other markets.

Bangladeshi Brands: Lanib, Lenvaxen, and Lenvanix

We source and supply three Bangladeshi-manufactured lenvatinib brands, each produced by a licensed pharmaceutical manufacturer operating under Bangladesh’s national drug regulatory framework.

A key trust signal for procurement teams is the Bangladesh Drug Marketing Authorization applicable to this product category, which carries a validity period from April 24, 2018, to April 25, 2028 — confirming that these brands operate under active national regulatory authorization in their country of manufacture.

All three brands deliver lenvatinib in the same approved capsule strengths (4 mg and 10 mg) and are manufactured exclusively in Bangladesh. We do not source or supply lenvatinib brands manufactured outside Bangladesh. Procurement officers in Pakistan and other markets can contact us directly to confirm current stock availability for any of these three brands.

Regulatory Status in Pakistan

In Pakistan, the importation, registration, and distribution of pharmaceutical products — including oncology medicines such as lenvatinib — fall under the authority of the Drug Regulatory Authority of Pakistan (DRAP), accessible at dra.gov.pk. DRAP is responsible for evaluating and authorizing imported drug products before they may be legally marketed or dispensed within the country.

For imported oncology medicines sourced from Bangladesh, compliance with DRAP’s import authorization and registration requirements is a prerequisite for lawful procurement and supply. The specific registration status of any individual brand — including Lanib, Lenvaxen, or Lenvanix — may vary and is subject to change. Pakistani healthcare providers, hospital pharmacies, and procurement officers are strongly advised to verify the current DRAP registration or import authorization status of any lenvatinib brand directly with DRAP before initiating procurement.

Our role in this supply chain is that of a Bangladeshi pharmaceutical exporter. We supply Bangladeshi-manufactured brands and support buyers in navigating documentation requirements for cross-border pharmaceutical trade. We do not manufacture, register, or distribute products within Pakistan, and we do not represent DRAP or make representations regarding local registration outcomes.

Important Safety Information and Precautions

Lenvatinib is an oncology medicine associated with serious risks that require active management by a qualified treating oncologist. As with all kinase inhibitors used in advanced cancer settings, lenvatinib carries a safety profile that demands careful patient selection, monitoring, and clinical oversight throughout the course of treatment.

Lactation: Based on the official prescribing information, patients are advised not to breastfeed during treatment with lenvatinib. Healthcare providers should counsel patients of childbearing potential regarding this guidance prior to initiating therapy.

Beyond lactation, lenvatinib’s full safety profile encompasses a range of potential serious adverse effects that are detailed in the complete prescribing information. Oncologists and clinical pharmacists responsible for managing patients on lenvatinib should consult the full prescribing information to ensure appropriate risk assessment, monitoring protocols, and patient counseling are in place.

Procurement teams and institutional buyers should note that lenvatinib is a prescription-only oncology agent. Its dispensing and administration must occur within a supervised clinical framework. Neither this article nor our supply services constitute medical advice. All treatment decisions — including initiation, continuation, and discontinuation of lenvatinib — remain the exclusive responsibility of the treating physician.

How to Order Lenvatinib for Pakistan — and Other Markets

We are a Bangladeshi pharmaceutical supplier specializing in the export of oncology medicines manufactured in Bangladesh. We export Lanib, Lenvaxen, and Lenvanix — our three available lenvatinib brands — to Pakistan as our primary destination market, and we also fulfill orders for buyers in India and Bangladesh.

All brands we supply are manufactured exclusively in Bangladesh. We do not source, stock, or distribute lenvatinib brands manufactured in India or any other country outside Bangladesh. Buyers seeking Indian-manufactured or other non-Bangladeshi brands should source those through alternative channels.

For context within the broader global market, the originator brand Lenva serves as a widely recognized reference product — our Bangladeshi-manufactured brands Lanib, Lenvaxen, and Lenvanix supply the same active molecule, lenvatinib, in the same approved capsule strengths.

To inquire about current stock availability, minimum order quantities, documentation support for DRAP import compliance, or general export logistics, please contact us directly using the inquiry form or contact details available on this website. Our team is available to assist hospital procurement departments, specialty pharmacies, and licensed importers in Pakistan and across the region.